Bibliography
- Jiaravuthisan MM, Sasseville D, Vender RB, Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007;57:1-27
- Gudjonsson JE, Karason A, Antonsdottir AA, HLA-Cw6-positive and HLA-Cw6-negative patients with Psoriasis vulgaris have distinct clinical features. J Invest Dermatol 2002;118:362-5
- Williamson L, Dalbeth N, Dockerty JL, Extended report: nail disease in psoriatic arthritis clinically important, potentially treatable and often overlooked. Rheumatology 2004;43:790-4
- Elkayam O, Ophir J, Yaron M, Caspi D. Psoriatic arthritis: interrelationships between skin and joint manifestations related to onset, course and distribution. Clin Rheumatol 2000;19:301-5
- de Jong EM, Seegers BA, Gulinck MK, Psoriasis of the nail associated with disability in a large number of patients: results of a recent interview with 1728 patients. Dermatology 1996;193:300-3
- De Berker D. Management of nail psoriasis. Clin Exp Dermatol 2000;25:357-62
- Bianchi L, Soda R, Diluvio L, Chimenti S. Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: an open prospective study. Br J Dermatol 2003;149:1207-9
- Lawry M. Biological therapy and nail psoriasis. Dermatol Ther 2007;20:60-7
- Reich K, Nestle FO, Papp K, Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74
- Bianchi L, Bergamin A, de Felice C, Remission and time of resolution of nail psoriasis during infliximab therapy. J Am Acad Dermatol 2005;52:736-7
- Nijsten T, Wakkee M. Psocare: italy shows the way in postmarketing studies. Dermatology 2008;217:362-4
- Pathirana D, Ormerod AD, Saiag P, European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009;23:1-70
- Smith CH, Anstey AV, Barker JN, British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009;161:987-1019
- Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003;49:206-12
- Weinberg JM. An overview of infliximab, etanercept, efalizumab, and alefacept as biological therapy for psoriasis. Clin Ther 2003;25:2487-505
- Rigopoulos D, Gregoriou S, Lazaridou E, Treatment of nail psoriasis with adalimumab: an open label unblinded study. J Eur Acad Dermatol Venereol 2010;24(5):530-4
- Rallis E, Stavropoulou E, Rigopoulos D, Verros C. Rapid response of nail psoriasis to etanercept. J Rheumatol 2008;35:544-5
- Luger TA, Barker J, Lambert J, Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2009;23(8):896-904
- Kyriakou A, Patsatsi A, Sotiriadis D. Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study. J Dermatolog Treat 2012; [Epub ahead of print]